Drug Trial Radar · NCT05078385
Safety of Extracellular Vesicles for Burn Wounds
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Aug 10, 2023
Primary completion
Sep 5, 2024
Study completion Nov 19, 2024
Sponsor
- Lead sponsor
- Aegle TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Congressionally Directed Medical Research Programs
- First posted
- Oct 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.
Conditions
- Burns
Interventions
AGLE-102Drug
AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Examine the safety of applying up to three applications of EVs to deep 2nd degree burn wounds up to 600 cm2Time frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ryder Trauma Center
Miami, Florida
North Carolina Jaycee Burn Center
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.